Newsletter

Stay up to date on all things colon cancer. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

DC Vaccine in Colorectal Cancer

November 21, 2019

Overview

This study is assessing the safety, tolerability and immune response rate the of mDC3 vaccine in patients with colorectal cancer.

 

Study Information

Participants in this study will undergo apheresis, a medical procedure whereby blood is passed through a machine to separate its different components. They will receive the drug cyclophosphamide a few days before receiving the vaccine itself and will also receive a booster vaccine 8 weeks later. Blood will be taken weekly and participants will be monitored in order to assess the effects of the vaccine. The estimated total enrollment for the study is 12 participants. It began on March 12th 2019 and is predicted to be completed by October 2021.

 

Inclusion Criteria

 

  • Stage I and II hypermutated colorectal cancer (CRC)
  • Surgically resected disease
  • Male or female patients 18+ years of age
  • ECOG performance status 0-1
  • Certain laboratory values, performed within 14 days prior to consent
  • Subjects of reproductive potential must agree to use a medically accepted birth control method during the trial and for at least two months following the trial.
  • Provide written informed consent

 

Exclusion Criteria

 

  • Prior malignancy within 3 years that may put subject at risk
  • Pregnant or nursing women
  • Concurrent treatment with systemic immunosuppressants including corticosteroids, calcineurin inhibitors, antiproliferative agents within 2 weeks of consent. Local (inhaled or topical) steroids or replacement dose prednisone are permitted.
  • Known allergy to eggs
  • Any uncontrolled intercurrent illness or active ongoing infection that may put subject at additional risk

 

Location

This study is taking place at the University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104. For more information, please contact Emerging Medicine on 855.216.0098 or at PennCancerTrials@emergingmed.com.

 

Sponsors/Collaborators

This study is Sponsored by the University of Pennsylvania, with Kim Reiss-Binder, MD. as the Principal Investigator.

Clinical Trials

View All Clinical Trials

Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk

This diet-intervention trial focuses on African American subjects who are at higher risk for developing colorectal cancer (CRC). Two diets, one…

Green Tea and Milk Thistle to Colorectal Cancer Patients

Colorectal cancer is the third most common form of cancer found in the United States, and surgical resection (removal) provides the best chance for…

Participatory Research to Advance Colon Cancer Prevention

The goal of this study is to test strategies to raise rates of colorectal cancer screening among the Latino population. This study will be split…

Reducing Rural Colon Cancer Disparities

This study is exploring the difference in outcomes for cancer patients in rural vs. urban areas. Southern Illinois will be used as the prime…

Young-Onset Microsatellite-Stable Colorectal Cancer

The goal of this laboratory research study is to learn more about genetic factors that may influence the risk for developing colorectal cancer at a…

PalloV-CC in Colon Cancer

This study is looking at the effects of the PalloV CC vaccination on patients with colon cancer. The primary goals are to understand the safety of…

Exercise And Colon Cancer Treatment

This study is looking at how exercise may prevent the recurrence of colon cancer in patients who have completed their treatment. The primary…

Niclosamide in Patients With Resectable Colon Cancer

This study is examining the safety of the drug Niclosamide in patients with colon cancer that are undergoing primary resection (cutting out) of…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend